NextBio Announces Translational Medicine Partnership with Sanofi

       NextBio Announces Translational Medicine Partnership with Sanofi

PR Newswire

SANTA CLARA, Calif., April 30, 2013

SANTA CLARA, Calif., April 30, 2013 /PRNewswire/ --NextBio today announced a
multi-year collaboration with Sanofi (NYSE:SNY) aimed at using NextBio
Clinical to incorporate patient omics and clinical data into Sanofi's drug
research and development, as part of Sanofi's Translational Medicine for
Patients (TM4P) program.

(Logo: http://photos.prnewswire.com/prnh/20130402/SF86976LOGO)

NextBio will provide Sanofi with the NextBio Clinical platform for
aggregation, standardization and analysis of patient clinical data, next
generation sequencing (NGS) and other molecular data across public data
sources, Sanofi clinical trials and Sanofi hospital partners. NextBio's unique
data integration platform, user interface and real-time Big Data analytics
will allow Sanofi biologists and clinicians to tap into a vast, growing
collection of patient data as it becomes available, as a key enabling
technology for translational and clinical research.

"Sanofi has long used NextBio as an important component of the company's
preclinical research programs," said Saeid Akhtari, President and Chief
Executive Officer of NextBio. "The new translational medicine partnership with
NextBio, with its Big Data Genomics capabilities, will enable Sanofi to
implement patient-centered approaches across all stages of translational and
clinical research in several major therapeutic areas, including oncology and
diabetes."

About NextBio

NextBio provides a state of the art scientific platform to aggregate and
interpret large quantities of molecular and other life sciences data for
research and clinical applications. NextBio's platform integrates data from
multiple repositories and diverse technologies by means of a unique
correlation engine, which pre-computes billions of significant connections
between disparate public and proprietary clinical and experimental data. This
feature enables interpretation of an individual's molecular data. It also
provides translational researchers the ability to look across the clinical and
molecular data of entire populations for clinical trial stratification and
selection, hypotheses generation, and biomarker discovery. NextBio Clinical,
which in 2012 passed an independent HIPAA audit, is designed for seamless
integration with existing clinical and research systems. Backed by highly
scalable, Big Data technology, it is capable of analyzing petabytes of data.
NextBio's platform is delivered as a SaaS (Software as a Service) solution
resulting in quick deployment and rapid return on investment.

Today, NextBio is used by researchers and clinicians in over 50 top commercial
and academic institutions including the National Institute of Health, The
University of Southern California, Sanford-Burnham Medical Research Institute,
Sanofi, Pfizer, Novartis, Celgene, Eli Lilly, Genzyme, Johnson & Johnson,
Merck, Regeneron, GlaxoSmithKline, Harvard Medical School, Scripps Research
Institute, Stanford University, University of California at Berkeley, Takeda
and many others. To learn more about NextBio, please visit our website at
http://www.nextbio.com.

SOURCE NextBio

Website: http://www.nextbio.com
Contact: Saeid Akhtari, President and CEO, NextBio, saeid@nextbio.com, Joan
Kureczka, Kureczka/Martin Associates, (415) 821 2413, Mobile: (415) 690-0210,
Joan@Kureczka-Martin.com